Aortic Stenosis Clinical Trial
Official title:
Assessment of Myocardial Tissue Damage in Aortic Stenosis for Risk Stratification
Aortic stenosis (AS) is the most common valve disease in the United States and most common
indication for valve replacement surgery. Anatomical and hemodynamic severity of AS is
insufficient for elucidating patients' prognosis. Therefore, the decision about the optimal
timing of surgical intervention remains critical. However, the changes in structure and
electrical activity of the cardiac muscle can be assessed by noninvasive imaging and
electrocardiography (ECG). Degenerative myocardial changes characterized by fibrosis or
collagen deposits are frequently observed in AS patients and have a negative impact on
patient outcomes. In this project, our objective is to determine whether echocardiographic
image analysis of integrated backscatter (IB), which can express changes in myocardial
tissue composition (amount of fibrosis) based on its ultrasound reflectivity, global left
ventricular (LV) load as measured by Zva, and ECG analysis of the duration of the QRS
interval have a role in risk stratification for AS patients and to apply those methods to
identify which patients would benefit from surgical intervention.
The investigators hypothesize that 1) the severity of myocardial damage can discriminate the
prognosis in patients with AS, and 2) IB, Zva, and QRS interval can be diagnostic measures
of the severity of myocardial damage. The investigators will measure the severity of
myocardial fibrosis using MRI (reference) in 50 patients and will test the diagnostic
significance of IB (testing method). Zva, QRS duration, and conventional echocardiographic
measures will also be tested for diagnosing severity of myocardial fibrosis.
n/a
Observational Model: Case-Only, Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04310046 -
Optimal Timing of Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention - The TAVI PCI Trial
|
N/A | |
Completed |
NCT03332745 -
Mechanism of Decompensation Evaluation - Aortic Stenosis
|
||
Recruiting |
NCT06008080 -
Post-Market Clinical Follow Up Study With Navitor Valve
|
||
Recruiting |
NCT06055751 -
Long Term Evaluation of Cardiac Arrhythmias After Transcatheter Aortic Valve Implantation -The LOCATE Registry
|
||
Active, not recruiting |
NCT04815785 -
Safety and Efficacy of TaurusOne® Transcatheter Aortic Valve System in Patients With Severe Calcific Aortic Stenosis
|
N/A | |
Terminated |
NCT02202434 -
Safety and Efficacy Study of Lotus Valve for Transcatheter Aortic Valve Replacement
|
N/A | |
Recruiting |
NCT03029026 -
The Role of Occult Cardiac Amyloid in the Elderly With Aortic Stenosis.
|
||
Active, not recruiting |
NCT02903420 -
A Clinical Trial of Transcatheter Aortic Valves in Dialysis Patients (Japan)
|
N/A | |
Completed |
NCT02629328 -
CardioCel Tri-leaflet Repair Study
|
N/A | |
Completed |
NCT02306226 -
Symetis ACURATE Neo™ Valve Implantation SAVI TF Registry
|
||
Withdrawn |
NCT01648309 -
Neuropsychological Testing in Patients Undergoing Transvascular Aortic Valve Implantation
|
N/A | |
Completed |
NCT01676727 -
ADVANCE Direct Aortic Study
|
||
Completed |
NCT01422044 -
Risk Prediction in Aortic Stenosis
|
N/A | |
Withdrawn |
NCT00774657 -
Ventricular Remodeling In Patients With Aortic Stenosis Assessed Echocardiography
|
N/A | |
Terminated |
NCT00535899 -
Speckle Tracking Imaging in Patients With Low Ejection Fraction Aortic Stenosis (SPArKLE-AS)
|
N/A | |
Terminated |
NCT05070130 -
OpSens PRIME CLASS
|
||
Completed |
NCT03314857 -
China XT: Safety and Effectiveness of Edwards Lifesciences SAPIEN XT THV in the Chinese Population
|
N/A | |
Completed |
NCT04157920 -
Impact of Predilatation Between Self-expanding Valves
|
N/A | |
Enrolling by invitation |
NCT06212050 -
Feasibility, Safety, and Effectiveness of the ACURATE neo2 Transcatheter Heart Valve for Severe Bicuspid Aortic Stenosis
|
||
Recruiting |
NCT05893082 -
Multicenter Feasibility Trial of the F2 Filter and Delivery System for Embolic Protection During TAVR
|
N/A |